How should ferric carboxymaltose be administered intravenously?

How to Administer Ferric Carboxymaltose (Injectafer)

Ferric carboxymaltose should be diluted in 100 mL of normal saline and infused intravenously over 20-30 minutes, with doses of 750 mg in the United States (two doses one week apart) or up to 1000 mg as a single infusion in Europe and Asia. 1

Dosing Regimens

United States FDA-Approved Dosing

• Standard dose: 750 mg per infusion, administered as two separate doses at least 7 days apart (total 1500 mg) 2
• Alternative: Up to 1000 mg as a single dose (though US labeling emphasizes 750 mg vials) 1
• Pediatric dosing (≥1 year): 15 mg/kg, not to exceed maximum single doses 2

International Dosing

• Europe/Asia: Routinely administered as 1000 mg single infusion 1
• Maximum single dose can reach 1000 mg when given over 15-30 minutes 1

Administration Technique

Preparation

1. Dilute ferric carboxymaltose in 100 mL of normal saline 1
2. Do not use other diluents
3. Each mL contains 50 mg of elemental iron 2

Infusion Protocol

1. Start the infusion slowly and observe the patient for several minutes 1
2. If no reaction occurs, complete the infusion over the remaining 20-30 minutes 1
3. Total infusion time: 20-30 minutes for full dose 1
4. Faster administration possible: Some studies show 15-minute infusions are safe 1, 3

Monitoring During Infusion

• Observe for acute onset of minor infusion reactions throughout administration 1
• Watch for complement activation-related pseudo-allergy (can mimic true allergic reactions) 4
• For mild reactions: Stop infusion, wait 15 minutes, restart at slower rate 4
• Avoid diphenhydramine - its side effects can be mistaken for worsening reactions 4

Critical Safety Considerations

Hypophosphatemia Risk

Ferric carboxymaltose has a unique association with treatment-emergent hypophosphatemia and should be avoided in patients requiring repeat infusions. 1

• Risk is lower in heart failure patients (8.1%) compared to other populations 5
• Risk increases with:
  • Multiple infusions
  • Higher cumulative doses
  • Preserved kidney function (eGFR >60 mL/min/1.73 m²) 6, 5
• Most cases are asymptomatic and transient 6
• Hypophosphatemic osteomalacia is rare but reported with repeated high-cumulative courses 2

Who Should NOT Receive Repeated FCM

• Patients with ongoing iron losses requiring frequent repletion 1
• Those needing long-term repeated iron therapy 6
• Consider alternative IV iron formulations (ferric derisomaltose, ferumoxytol) for these patients 1

Monitoring Recommendations

• Low-risk patients: Routine phosphate monitoring NOT recommended 6
• High-risk patients (multiple infusions, high doses, preserved renal function): Monitor serum phosphate 6
• Check CBC and iron parameters (ferritin, TSAT) 4-8 weeks after last infusion - not sooner 1

Clinical Efficacy Context

Ferric carboxymaltose demonstrates:

• Rapid hemoglobin improvement: Mean increase 0.95-2.9 g/dL by day 35-42 2, 7
• Superior to oral iron in multiple trials 2, 7
• First IV iron showing cardiovascular benefit in heart failure patients 1
• Effective across multiple conditions: CKD, pregnancy, heavy uterine bleeding, IBD, heart failure 1, 8

Practical Advantages

• Fewer infusions required compared to iron sucrose (1-2 vs 3-5 infusions) 3
• Rapid administration (15-30 minutes vs hours for older formulations) 1, 9
• Well-tolerated: Treatment-related adverse events only 2.7% vs 26.2% with oral iron 7

Common Pitfalls to Avoid

1. Don't check iron parameters too early - wait 4-8 weeks post-infusion 1
2. Don't use FCM for repeated dosing - switch to alternative IV iron to avoid hypophosphatemia 1, 6
3. Don't premedicate with diphenhydramine - can confuse reaction assessment 4
4. Don't waste medication - US 750 mg vials require careful dose planning to avoid discarding 500 mg if only 1000 mg total is needed 1